BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

903 related articles for article (PubMed ID: 30345007)

  • 1. Recent trends in the management of advanced prostate cancer.
    Ritch C; Cookson M
    F1000Res; 2018; 7():. PubMed ID: 30345007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    Damodaran S; Lang JM; Jarrard DF
    J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate.
    Giacinti S; Carlini P; Roberto M; Bassanelli M; Strigari L; Pavese F; Aschelter AM; Felici A; Valeriani M; Cognetti F; Marchetti P
    Anticancer Drugs; 2017 Jan; 28(1):110-115. PubMed ID: 27763885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abiraterone acetate to treat metastatic castration-resistant prostate cancer in combination with prednisone.
    Duarte C; Jimeno A; Kessler ER
    Drugs Today (Barc); 2019 Jan; 55(1):5-15. PubMed ID: 30740608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermittent androgen deprivation therapy in advanced prostate cancer.
    Alva A; Hussain M
    Curr Treat Options Oncol; 2014 Mar; 15(1):127-36. PubMed ID: 24395278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of hormone-naïve metastatic prostate cancer.
    Hamilou Z; Saad F; Fizazi K
    Curr Opin Support Palliat Care; 2018 Sep; 12(3):334-338. PubMed ID: 30015691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of targeting intracrinology in prostate cancer management.
    Hamid ARAH; Tendi W; Sesari SS; Mochtar CA; Umbas R; Verhaegh G; Schalken JA
    World J Urol; 2019 May; 37(5):751-757. PubMed ID: 30350016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review.
    Caffo O; Veccia A; Kinspergher S; Maines F
    Future Oncol; 2018 Feb; 14(5):431-442. PubMed ID: 29350549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.
    Wallis CJD; Klaassen Z; Bhindi B; Goldberg H; Chandrasekar T; Farrell AM; Boorjian SA; Kulkarni GS; Karnes RJ; Satkunasivam R
    Eur Urol; 2018 Jun; 73(6):834-844. PubMed ID: 29037513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abiraterone acetate in the treatment of prostate cancer.
    Thakur A; Roy A; Ghosh A; Chhabra M; Banerjee S
    Biomed Pharmacother; 2018 May; 101():211-218. PubMed ID: 29494958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer.
    Saad F; Fizazi K
    Urology; 2015 Nov; 86(5):852-61. PubMed ID: 26282624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes and prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy: a retrospective multicenter study in Japan.
    Narita S; Hatakeyama S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Koizumi A; Mitsuzuka K; Tochigi T; Tsuchiya N; Ohyama C; Arai Y; Nomura K; Habuchi T
    Int J Clin Oncol; 2020 May; 25(5):912-920. PubMed ID: 31919691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Metastatic prostate cancer : Update: position paper for the use of chemotherapy].
    Ohlmann CH; Goebell PJ; Grimm MO; Klier J; König F; Machtens S; Schostak M; Schrader AJ; Albers P
    Urologe A; 2017 Dec; 56(12):1597-1602. PubMed ID: 28695241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.
    Ferraldeschi R; Nava Rodrigues D; Riisnaes R; Miranda S; Figueiredo I; Rescigno P; Ravi P; Pezaro C; Omlin A; Lorente D; Zafeiriou Z; Mateo J; Altavilla A; Sideris S; Bianchini D; Grist E; Thway K; Perez Lopez R; Tunariu N; Parker C; Dearnaley D; Reid A; Attard G; de Bono J
    Eur Urol; 2015 Apr; 67(4):795-802. PubMed ID: 25454616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy.
    Manceau C; Mourey L; Pouessel D; Ploussard G
    Expert Rev Anticancer Ther; 2020 Aug; 20(8):629-638. PubMed ID: 32552120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen deprivation therapy with chemotherapy or abiraterone for patients with metastatic hormone-naive prostate cancer: a systematic review and meta-analysis.
    Sun G; Chen X; Gong U; Chen Y; Li G; Wei F; Jiang A; Niu Y; Shang Z
    Future Oncol; 2019 Apr; 15(10):1167-1179. PubMed ID: 30741558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
    Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
    Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis.
    Wang L; Hong H; Alexander GC; Brawley OW; Paller CJ; Ballreich J
    Value Health; 2022 May; 25(5):796-802. PubMed ID: 35500949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.